859 related articles for article (PubMed ID: 16784448)
21. DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.
Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T; Baró-Tomás T; Alía-Aponte C; Lázera MS
Mycopathologia; 2005 Aug; 160(1):9-14. PubMed ID: 16160762
[TBL] [Abstract][Full Text] [Related]
22. [In vitro antifungal susceptibility of dematiaceous filamentous fungi using the E-test].
Vivas JR; Torres-Rodríguez JM
Rev Esp Quimioter; 2001 Jun; 14(2):191-7. PubMed ID: 11704774
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
25. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
27. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
Liaw SJ; Wu HC; Hsueh PR
Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
[TBL] [Abstract][Full Text] [Related]
28. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
29. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
Fujita S
Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821
[TBL] [Abstract][Full Text] [Related]
30. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
[TBL] [Abstract][Full Text] [Related]
31. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
32. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
34. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
35. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
Souza LK; Souza Junior AH; Costa CR; Faganello J; Vainstein MH; Chagas AL; Souza AC; Silva MR
Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
[TBL] [Abstract][Full Text] [Related]
36. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques.
Moraes EM; Prímola NS; Hamdan JS
Mycoses; 2003 Jun; 46(5-6):164-8. PubMed ID: 12801356
[TBL] [Abstract][Full Text] [Related]
37. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil.
Pedroso RS; Ferreira JC; Candido RC
Mem Inst Oswaldo Cruz; 2006 May; 101(3):239-43. PubMed ID: 16862315
[TBL] [Abstract][Full Text] [Related]
39. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
Soares BM; Santos DA; Kohler LM; da Costa César G; de Carvalho IR; dos Anjos Martins M; Cisalpino PS
Rev Iberoam Micol; 2008 Dec; 25(4):242-5. PubMed ID: 19071894
[TBL] [Abstract][Full Text] [Related]
40. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]